Senti Bio Details Celadon Merger: CVRs Worth Up to $60M, Reverse Split, and Liquidation Warning
SNTI is trading near its 52-week low of $0.424 (11% above the low) on elevated volume (2.6× avg).
Summary
Senti Bio's proxy details a Celadon-led merger that spins off SENTI-202 for CVRs worth up to $60M, while the company warns liquidation would leave shareholders with nothing. The deal includes a reverse stock split and a $2.5M breakup fee.
Key Events · M&A and Partnerships · SNTI
-
Merger Spins Off Lead Asset for CVRs
A Celadon-controlled entity will acquire SENTI-202 through a merger of Midco. Public stockholders receive one CVR per share, entitling them to up to $60M in aggregate milestone payments: $10M upon BLA acceptance, $20M upon FDA approval, and $30M upon $200M cumulative net sales, all expiring in 7 years.
-
Liquidation Analysis Shows Zero Recovery
Management's liquidation analysis estimates a negative equity value of -$27.6M to -$23.3M, implying $0.00 per share for common stockholders. The company has a going-concern warning and cash runway only into Q3 2026.
-
Fairness Opinion Values CVRs at $0.07–$0.20/Share
Lincoln International's risk-adjusted present value of the CVRs is $0.07–$0.20 per share, reflecting low probability of success (18–42%) and long timelines (2030–2032). The maximum undiscounted payout is $1.05/share under current dilution.
-
Reverse Stock Split Proposed to Maintain Nasdaq Listing
Shareholders will vote on a reverse stock split at a ratio between 1-for-20 and 1-for-50 to boost the stock price above $1.00 and avoid delisting. The stock closed at $0.47 on July 21, 2026.
Analysis · SNTI · Life Sciences
Shareholders are being asked to approve a merger that spins off Senti Biosciences' lead asset, SENTI-202, to a Celadon-controlled private company. In return, public stockholders would receive contingent value rights (CVRs) that could pay up to $60 million if regulatory and sales milestones are met—yet the company's own analysis shows a liquidation would yield $0.00 per share. The deal includes a reverse stock split to maintain Nasdaq listing and a $2.5 million termination fee. The proxy reveals a deeply distressed company with a going-concern warning, no viable alternatives, and a controlling shareholder driving the transaction. Lincoln's fairness opinion values the CVRs at $0.07–$0.20 per share on a risk-adjusted basis, far below the maximum potential payout, underscoring the high risk of no payment.
At the time of this filing, SNTI was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.3M. The 52-week trading range was $0.42 to $2.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.